Jingping Mo
Pfizer
10 Papers
5 Citations
Jingping Mo is an academic researcher from Pfizer. The author has contributed to research in topics: Cohort study & Varenicline. The author has an hindex of 3, co-authored 10 publications.
Chat about Author
Papers
The Structured Process to Identify Fit-For-Purpose Data: A Data Feasibility Assessment Framework.
Nicolle M. Gatto,Nicolle M. Gatto,Ulka B. Campbell,Ulka B. Campbell,Emily Rubinstein,Ashley Jaksa,Pattra Mattox,Jingping Mo,Robert F. Reynolds,Robert F. Reynolds +9 more
TL;DR: In this article, a structured framework for conducting feasibility assessments is proposed to identify decision grade, fit-for-purpose data, which complements the United States Food and Drug Administration (FDA)'s framework for a RWE program.
35
The effectiveness of varenicline medication guide for conveying safety information to patients: a REMS assessment survey.
TL;DR: The effectiveness of the varenicline MG as a REMS tool for educating patients, which provides key information regarding the potential risks associated with the medication, is evaluated.
23
Risk of adverse birth outcomes after maternal varenicline use: A population-based observational study in Denmark and Sweden.
Lars Pedersen,Kenneth R. Petronis,Mette Nørgaard,Jingping Mo,Trine Frøslev,Olof Stephansson,Fredrik Granath,Helle Kieler,Henrik Toft Sørensen +8 more
TL;DR: To examine risks of adverse birth outcomes in women exposed to varenicline during pregnancy, a large number of women were exposed to the substance during pregnancy and the birth of their children.
12
Classification and characteristics of on-label and off-label apixaban use in Denmark and Sweden.
Nicklas Vinter,Marie Linder,Morten Andersen,Morten Andersen,Alma B Pedersen,Morten Madsen,Stephen E. Schachterle,Stephen E. Schachterle,Quazi Ataher,Jingping Mo,Søren Paaske Johnsen,Vera Ehrenstein +11 more
TL;DR: To estimate the proportion of apixaban users who received the drug for on‐label indications and characterise the patients using Apixaban for on-label and off-label indications, a large number of patients from across Europe and Asia were recruited.
6
Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United States.
Vera Ehrenstein,Kui Huang,Johnny Kahlert,Shahram Bahmanyar,Pär Karlsson,Lukas Löfling,Anthony P. Nunes,Cheryl Enger,Irene D. Bezemer,Josephina G. Kuiper,Fabian Hoti,Rosa Juuti,Pasi K. Korhonen,Jingping Mo,Stephen E. Schachterle,Stephen E. Schachterle,Keith D. Wilner,Mikael Rørth,Henrik Toft Sørensen +18 more
TL;DR: In this article, the authors examined safety outcomes of interest (SOI) and overall survival (OS) among lung cancer patients initiating crizotinib and erlotinib in routine clinical practice.
5